No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?

Cheol Kwak, Yong Hyun Park, Chang Wook Jeong, Sang Eun Lee, Ja Hyeon Ku

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Objective: To compare the effects of metastasectomy combined with immunotherapy and metastasectomy alone in the treatment of patients with metastatic renal cell carcinoma. Materials and Methods: A total of 93 patients who had undergone metastasectomy were included in the study. Patients were categorized according to immunotherapy status, including the immunotherapy group (n = 70) and the no immunotherapy group (n = 23). Results: In the immunotherapy group, median overall survival was 56.1 months (95% confidence interval [CI] 34.1-78.2), whereas the no immunotherapy group reached a median overall survival of 21.3 months (95% CI 3.4-39.2), respectively. The 1, 3, and 5-year overall survival rates were calculated at 67.1% and 56.5%, 30.0% and 34.8%, and 7.1% and 19.0%, for the immunotherapy group and the no immunotherapy group, respectively (P = 1.000). When patients were stratified according to the time of metastasis, overall survival was not significantly different among the groups in patients with synchronous metastasis or in those with metachronous metastasis. Multivariate Cox proportional hazards model analysis showed that multiplicity of metastasis (odds ratio 3.68; 95% CI 1.85-7.34; P < 0.001) and metastatic sites (odds ratio 2.12; 95% CI 1.15-3.90; P = 0.016) were independent predictors of overall survival. Conclusions: Metastasectomy combined with adjuvant immunotherapy did not result in a significantly higher overall survival rate as compared with metastasectomy alone. Our findings raise the question of "Is there a role of adjuvant immunotherapy after complete metastasectomy in patients with metastatic renal cell carcinoma?".

Original languageEnglish
Pages (from-to)310-316
Number of pages7
JournalUrologic Oncology: Seminars and Original Investigations
Volume25
Issue number4
DOIs
StatePublished - 1 Jul 2007

Fingerprint

Metastasectomy
Renal Cell Carcinoma
Immunotherapy
Confidence Intervals
Neoplasm Metastasis
Therapeutics
Survival
Survival Rate
Odds Ratio
Proportional Hazards Models

Keywords

  • Immunotherapy
  • Metastasectomy
  • Metastasis
  • Nephrectomy
  • Renal cell carcinoma

Cite this

@article{f713d0a7625948b6ac7799885d0e5cc3,
title = "No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?",
abstract = "Objective: To compare the effects of metastasectomy combined with immunotherapy and metastasectomy alone in the treatment of patients with metastatic renal cell carcinoma. Materials and Methods: A total of 93 patients who had undergone metastasectomy were included in the study. Patients were categorized according to immunotherapy status, including the immunotherapy group (n = 70) and the no immunotherapy group (n = 23). Results: In the immunotherapy group, median overall survival was 56.1 months (95{\%} confidence interval [CI] 34.1-78.2), whereas the no immunotherapy group reached a median overall survival of 21.3 months (95{\%} CI 3.4-39.2), respectively. The 1, 3, and 5-year overall survival rates were calculated at 67.1{\%} and 56.5{\%}, 30.0{\%} and 34.8{\%}, and 7.1{\%} and 19.0{\%}, for the immunotherapy group and the no immunotherapy group, respectively (P = 1.000). When patients were stratified according to the time of metastasis, overall survival was not significantly different among the groups in patients with synchronous metastasis or in those with metachronous metastasis. Multivariate Cox proportional hazards model analysis showed that multiplicity of metastasis (odds ratio 3.68; 95{\%} CI 1.85-7.34; P < 0.001) and metastatic sites (odds ratio 2.12; 95{\%} CI 1.15-3.90; P = 0.016) were independent predictors of overall survival. Conclusions: Metastasectomy combined with adjuvant immunotherapy did not result in a significantly higher overall survival rate as compared with metastasectomy alone. Our findings raise the question of {"}Is there a role of adjuvant immunotherapy after complete metastasectomy in patients with metastatic renal cell carcinoma?{"}.",
keywords = "Immunotherapy, Metastasectomy, Metastasis, Nephrectomy, Renal cell carcinoma",
author = "Cheol Kwak and Park, {Yong Hyun} and Jeong, {Chang Wook} and Lee, {Sang Eun} and Ku, {Ja Hyeon}",
year = "2007",
month = "7",
day = "1",
doi = "10.1016/j.urolonc.2006.08.022",
language = "English",
volume = "25",
pages = "310--316",
journal = "Urologic Oncology: Seminars and Original Investigations",
issn = "1078-1439",
publisher = "Elsevier Inc.",
number = "4",

}

No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma? / Kwak, Cheol; Park, Yong Hyun; Jeong, Chang Wook; Lee, Sang Eun; Ku, Ja Hyeon.

In: Urologic Oncology: Seminars and Original Investigations, Vol. 25, No. 4, 01.07.2007, p. 310-316.

Research output: Contribution to journalArticle

TY - JOUR

T1 - No role of adjuvant systemic therapy after complete metastasectomy in metastatic renal cell carcinoma?

AU - Kwak, Cheol

AU - Park, Yong Hyun

AU - Jeong, Chang Wook

AU - Lee, Sang Eun

AU - Ku, Ja Hyeon

PY - 2007/7/1

Y1 - 2007/7/1

N2 - Objective: To compare the effects of metastasectomy combined with immunotherapy and metastasectomy alone in the treatment of patients with metastatic renal cell carcinoma. Materials and Methods: A total of 93 patients who had undergone metastasectomy were included in the study. Patients were categorized according to immunotherapy status, including the immunotherapy group (n = 70) and the no immunotherapy group (n = 23). Results: In the immunotherapy group, median overall survival was 56.1 months (95% confidence interval [CI] 34.1-78.2), whereas the no immunotherapy group reached a median overall survival of 21.3 months (95% CI 3.4-39.2), respectively. The 1, 3, and 5-year overall survival rates were calculated at 67.1% and 56.5%, 30.0% and 34.8%, and 7.1% and 19.0%, for the immunotherapy group and the no immunotherapy group, respectively (P = 1.000). When patients were stratified according to the time of metastasis, overall survival was not significantly different among the groups in patients with synchronous metastasis or in those with metachronous metastasis. Multivariate Cox proportional hazards model analysis showed that multiplicity of metastasis (odds ratio 3.68; 95% CI 1.85-7.34; P < 0.001) and metastatic sites (odds ratio 2.12; 95% CI 1.15-3.90; P = 0.016) were independent predictors of overall survival. Conclusions: Metastasectomy combined with adjuvant immunotherapy did not result in a significantly higher overall survival rate as compared with metastasectomy alone. Our findings raise the question of "Is there a role of adjuvant immunotherapy after complete metastasectomy in patients with metastatic renal cell carcinoma?".

AB - Objective: To compare the effects of metastasectomy combined with immunotherapy and metastasectomy alone in the treatment of patients with metastatic renal cell carcinoma. Materials and Methods: A total of 93 patients who had undergone metastasectomy were included in the study. Patients were categorized according to immunotherapy status, including the immunotherapy group (n = 70) and the no immunotherapy group (n = 23). Results: In the immunotherapy group, median overall survival was 56.1 months (95% confidence interval [CI] 34.1-78.2), whereas the no immunotherapy group reached a median overall survival of 21.3 months (95% CI 3.4-39.2), respectively. The 1, 3, and 5-year overall survival rates were calculated at 67.1% and 56.5%, 30.0% and 34.8%, and 7.1% and 19.0%, for the immunotherapy group and the no immunotherapy group, respectively (P = 1.000). When patients were stratified according to the time of metastasis, overall survival was not significantly different among the groups in patients with synchronous metastasis or in those with metachronous metastasis. Multivariate Cox proportional hazards model analysis showed that multiplicity of metastasis (odds ratio 3.68; 95% CI 1.85-7.34; P < 0.001) and metastatic sites (odds ratio 2.12; 95% CI 1.15-3.90; P = 0.016) were independent predictors of overall survival. Conclusions: Metastasectomy combined with adjuvant immunotherapy did not result in a significantly higher overall survival rate as compared with metastasectomy alone. Our findings raise the question of "Is there a role of adjuvant immunotherapy after complete metastasectomy in patients with metastatic renal cell carcinoma?".

KW - Immunotherapy

KW - Metastasectomy

KW - Metastasis

KW - Nephrectomy

KW - Renal cell carcinoma

UR - http://www.scopus.com/inward/record.url?scp=34447098702&partnerID=8YFLogxK

U2 - 10.1016/j.urolonc.2006.08.022

DO - 10.1016/j.urolonc.2006.08.022

M3 - Article

C2 - 17628297

AN - SCOPUS:34447098702

VL - 25

SP - 310

EP - 316

JO - Urologic Oncology: Seminars and Original Investigations

JF - Urologic Oncology: Seminars and Original Investigations

SN - 1078-1439

IS - 4

ER -